TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9127120

Group type: EXPERIMENTAL
Intervention: Blood-volume-pulse biofeedback followed by cognitive behavioral therapy (Group I)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy followed by blood-volume-pulse biofeedback (Group II)
Number of subjects: 38
Study: 1337291

Group type: EXPERIMENTAL
Intervention: Naloxone (0.015 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone (both doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone (low dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beta-endorphin levels
Number of subjects: 10
Study: 3025927

Group type: COMPARATOR
Intervention: Org 2766
Number of subjects: 156
Study: 30057048

Group type: EXPERIMENTAL
Intervention: Momordica charantia (500 mg per capsule, three times daily for 3 months)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 27098820

Group type: EXPERIMENTAL
Intervention: Stepwise implementation administered and monitored in a quarterly rheumatological nurse‐administered set‐up targeting hyperlipidaemia, hypertension, hyperglycaemia, and microalbuminuria
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional treatment administered and monitored by general practitioner according to national guidelines
Number of subjects: 300
Study: 24490888

Group type: EXPERIMENTAL
Intervention: Yoghurt enriched with alpha‐lactalbumin, casein tripeptides and B vitamins
Number of subjects: 67
Study: 22569236

Group type: EXPERIMENTAL
Intervention: VLCD+E (Very Low-Calorie Diet + Exercise)
Number of subjects: 27

Group type: COMPARATOR
Intervention: VLCD-only (Very Low-Calorie Diet only)
Number of subjects: 27
Study: 19079825

Group type: EXPERIMENTAL
Intervention: Emotional over-involvement (EOI)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Critical comments (CC)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Baseline Emotional over-involvement (EOI)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Family burden of care at follow-up
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Carers' critical comments (CC) at follow-up
Number of subjects: 63
Study: 18823658

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once a day, increased to 32 mg once a day after one month
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 1905
Study: 15824508

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (5 doses of 200 mg weekly)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Oral FeSO4 (325 mg t.i.d.)
Number of subjects: 96
Study: 12575874

Group type: EXPERIMENTAL
Intervention: Active Appearance Motion Model (AAMM)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Nonlinear intensity normalization
Number of subjects: 129
Study: 10383527

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. in H. pylori-negative patients
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. in H. pylori-positive patients
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d. in H. pylori-negative patients
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.d. in H. pylori-positive patients
Number of subjects: 58
Study: 8944109

Group type: EXPERIMENTAL
Intervention: Slit-lamp supported biometry
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hand-held biometry
Number of subjects: 32
Study: 1683355

Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin therapy (loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 mg/kg every 8 h for 3 days)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin therapy
Number of subjects: 242
Study: 6753092

Group type: EXPERIMENTAL
Intervention: Flunisolide (topical corticosteroid)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30222087

Group type: EXPERIMENTAL
Intervention: X:IT intervention
Number of subjects: 3269

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 3269
Study: 29410968

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (1 g TXA intravenously)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Topical TXA (3 g TXA in 100 ml saline intra-articularly)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (saline both intravenously and intra-articularly)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intravenous TXA vs Topical TXA
Number of subjects: 93
Study: 25544738

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dose-escalation intervention after 6 weeks
Number of subjects: 70
Study: 24550216

Group type: EXPERIMENTAL
Intervention: GCK‐MODY diagnosis in women with fasting glucose ≥5.1 mmol/L
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Clinical criteria for differentiating GCK‐MODY from GDM
Number of subjects: 247

Group type: COMPARATOR
Intervention: Population prevalence of GDM
Number of subjects: 247
Study: 22779287

Group type: EXPERIMENTAL
Intervention: sugar‐free stick gum (Wrigley's Extra Freshmint)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: sugar‐free pellet gum (Wrigley's Extra Fruit)
Number of subjects: 42

Group type: COMPARATOR
Intervention: no‐gum chewing
Number of subjects: 42
Study: 19023614

Group type: EXPERIMENTAL
Intervention: Roux-en-Y (RY) reconstruction
Number of subjects: 70

Group type: COMPARATOR
Intervention: rho-shaped Roux-en-Y (rRY) reconstruction
Number of subjects: 70
Study: 17879532

Group type: EXPERIMENTAL
Intervention: Chaihu Taoren Decoction (CTD)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (TT homozygote)
Number of subjects: 119
Study: 15536655

Group type: EXPERIMENTAL
Intervention: Near-infrared (NIR) spectroscopy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Laser Doppler perfusion imaging
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Digital photography
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of all three techniques (NIR, Laser Doppler, Digital photography)
Number of subjects: 28
Study: 12559479

Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavior Scale (FrSBe)
Number of subjects: 131
Study: 9521168

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29133
Study: 8120705

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 125

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study: 2757878

Group type: EXPERIMENTAL
Intervention: Long acting propranolol 160 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Long acting propranolol 80 mg
Number of subjects: 12
Study: 7362091

Group type: EXPERIMENTAL
Intervention: Atropine nebulization at approximately 0.075 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isoetharine nebulization
Number of subjects: 10
Study: 31306433

Group type: EXPERIMENTAL
Intervention: Treatment for soil-transmitted helminth infection (specific interventions not detailed in the abstract)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Control group (children without soil-transmitted helminth infection)
Number of subjects: 434
Study: 28635026

Group type: EXPERIMENTAL
Intervention: ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ixekizumab 80 mg every 12 weeks (IXEQ12W)
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ixekizumab (any dosage)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ixekizumab (IXEQ12W, IXEQ4W)
Number of subjects: 33
Study: 25972257

Group type: EXPERIMENTAL
Intervention: Highest dietary riboflavin intake
Number of subjects: 3115

Group type: EXPERIMENTAL
Intervention: Highest dietary B12 intake
Number of subjects: 3115

Group type: EXPERIMENTAL
Intervention: Highest dietary B6 intake
Number of subjects: 3115

Group type: EXPERIMENTAL
Intervention: Highest dietary intake levels of niacin and B12
Number of subjects: 3115

Group type: EXPERIMENTAL
Intervention: Highest dietary folate intake
Number of subjects: 3115

Group type: EXPERIMENTAL
Intervention: Lutein plus zeaxanthin intake
Number of subjects: 3115
Study: 23375005

Group type: EXPERIMENTAL
Intervention: Physiotherapy (isometric training of abdominal muscles, diaphragmatic breathing exercises, and abdominal massage during 12 40‐min sessions twice a week) + laxatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication (laxatives only)
Number of subjects: 0
Study: 21284545

Group type: EXPERIMENTAL
Intervention: Autologous PRF and OFD
Number of subjects: 18

Group type: COMPARATOR
Intervention: OFD
Number of subjects: 18
Study: 18678578

Group type: EXPERIMENTAL
Intervention: rAAV2‐TNFR:Fc (1 x 10(10) DNase resistant particles per ml joint volume)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rAAV2‐TNFR:Fc (1 x 10(11) DNase resistant particles per ml joint volume)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17341245

Group type: EXPERIMENTAL
Intervention: Moderate to high disease severity score
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Diagnosis of pneumonia (confirmed by chest radiograph)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Oxygen saturation (<90%)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Diagnosis of congestive heart failure
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Receipt of pneumococcal vaccine
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Greater functional independence
Number of subjects: 353
Study: 16813906

Group type: EXPERIMENTAL
Intervention: Overactive bladder questionnaire (OBQ) symptom bother subscale
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Overactive bladder questionnaire (OBQ) health related quality of life subscales (coping, concern, sleep, social interaction)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Change scores in patients perceiving no and little benefit
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Micturition diary variables
Number of subjects: 2
Study: 12728754

Group type: EXPERIMENTAL
Intervention: Individualized education about proper foot care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine home care services (Control)
Number of subjects: 40
Study: 10336577

Group type: EXPERIMENTAL
Intervention: Clevidipine at target dose rates ranging from 0.12 to 48 nmol min‐1 kg‐1
Number of subjects: 25
Study: 8760089

Group type: EXPERIMENTAL
Intervention: Pulsatile GH delivery (10.7 ng.kg‐1.min‐1 for men, 15 ng.kg‐1.min‐1 for women, 60 min peak width, 15 min peak width at half-height)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Constant GH infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: GH deficiency
Number of subjects: 8
Study: 1744358

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) for 3 and 4 years
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-immunotherapy (non-IT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT)
Number of subjects: 25
Study: 6125103

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 102
Study: 29587831

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 400
Study: 27869715

Group type: EXPERIMENTAL
Intervention: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inositol-stabilized arginine silicate (ASI; Nitrosigine®) 1500 mg/day for a 10-min period
Number of subjects: 0
Study: 23764718

Group type: EXPERIMENTAL
Intervention: Flupirtine 100 mg
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 22940462

Group type: EXPERIMENTAL
Intervention: Behavioral anger expression in LBP patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Trait anger-out in LBP patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Daily anger expression in LBP patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Trait anger suppression (anger-in) in LBP patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Trait anger-out in individuals low in trait anger-out
Number of subjects: 48
Study: 21189770

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with bone graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bone graft alone (control group)
Number of subjects: 20
Study: 18364319

Group type: EXPERIMENTAL
Intervention: Evidence-based nutrition (EBN) interventions
Number of subjects: 0
Study: 15776331

Group type: EXPERIMENTAL
Intervention: CHO (10% glucose, 30 mmol . l (‐1) NaCl)
Number of subjects: 8

Group type: COMPARATOR
Intervention: W (water, 30 mmol . l (‐1) NaCl)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 8
Study: 11952072

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rectal diazepam
Number of subjects: 30
Study: 10622193

Group type: EXPERIMENTAL
Intervention: Sphygmomanometer cuff pressures (diastolic pressure - 30 mm Hg to diastolic pressure + 5 mm Hg)
Number of subjects: 0
Study: 7851585

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (normal ovarian cycles)
Number of subjects: 30
Study: 1781807

Group type: EXPERIMENTAL
Intervention: Cefadroxil plus N-acetylcysteine (1000 mg cefadroxil + 200 mg N-acetylcysteine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cefadroxil alone (1000 mg)
Number of subjects: 12
Study: 6982626

Group type: EXPERIMENTAL
Intervention: Thiopentone (3.0 mg/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Althesin (0.07 ml/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ketamine (1.5 mg/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.015 mg/kg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.01 mg/kg) added to Althesin and Flunitrazepam
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.01 mg/kg) added to Ketamine
Number of subjects: 46
Study: 31629649

Group type: COMPARATOR
Intervention: Control (repeated initial vaccination with HBVaxPro 10 μg or Engerix‐B 20 μg)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Twinrix 20 μg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: HBVaxPro 40 μg
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Fendrix 20 μg
Number of subjects: 480
Study: 31506951

Group type: EXPERIMENTAL
Intervention: Cluster randomized trials in school health research
Number of subjects: 0
Study: 28963290

Group type: EXPERIMENTAL
Intervention: So-Cheong-Ryong-Tang (SCRT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 25894667

Group type: EXPERIMENTAL
Intervention: Integrative cognitive‐affective therapy (ICAT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive‐behavioral therapy (CBT‐E)
Number of subjects: 80
Study: 22886490

Group type: EXPERIMENTAL
Intervention: Autologous pulsed dendritic cell vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 30
Study: 20653487

Group type: EXPERIMENTAL
Intervention: 1600 IU vitamin D(3) plus vitamin E placebo (group D)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 600 IU synthetic all‐rac‐α‐tocopherol plus vitamin D placebo (group E)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1600 IU vitamin D(3) plus 600 IU synthetic all‐rac‐α‐tocopherol (group DE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vitamins D and E placebos (group P)
Number of subjects: 45
Study: 19470928

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Program (CRP)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 140
Study: 17446997

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 163

Group type: COMPARATOR
Intervention: Normotensive
Number of subjects: 163
Study: 12585981

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional NSAIDs
Number of subjects: 0
Study: 11908374

Group type: EXPERIMENTAL
Intervention: Colgate Actibrush battery-powered toothbrush
Number of subjects: 110

Group type: COMPARATOR
Intervention: Colgate Plus Diamond Head Toothbrush (manual)
Number of subjects: 110
Study: 8737755

Group type: EXPERIMENTAL
Intervention: Intravenous Erythropoietin (IV EPO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subcutaneous Erythropoietin (SC EPO)
Number of subjects: 50
Study: 1351025

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg once a day
Number of subjects: 125

Group type: COMPARATOR
Intervention: Metoprolol 100 mg a day (50 mg twice a day)
Number of subjects: 125
Study: 6741192

Group type: EXPERIMENTAL
Intervention: Daily perseverance training of 60 min at about 50% VO2 max
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 144
Study: 30703172

Group type: EXPERIMENTAL
Intervention: Mask continue group
Number of subjects: 175

Group type: COMPARATOR
Intervention: Prong continue group
Number of subjects: 175

Group type: COMPARATOR
Intervention: Rotation group
Number of subjects: 175
Study: 30035399

Group type: EXPERIMENTAL
Intervention: Students with allergic diseases and a positive skin prick test (SPT)
Number of subjects: 1373

Group type: EXPERIMENTAL
Intervention: Students with allergic disease who were SPT negative
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Control group (students with no allergic diseases)
Number of subjects: 1373
Study: 25871403

Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV), a continuous weaning strategy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Biphasic positive airway pressure (BIPAP) with spontaneous breathing trials, a discontinuous technique
Number of subjects: 40
Study: 23522095

Group type: EXPERIMENTAL
Intervention: Integrated Disease Management (IDM)
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1086
Study: 21102473

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) treatment for a mean duration of 1 year
Number of subjects: 71

Group type: COMPARATOR
Intervention: No treatment or vitamin E
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) treatment
Number of subjects: 71
Study: 19920081

Group type: COMPARATOR
Intervention: Physician intervention (internet-based training, self-monitoring, quarterly feedback reports)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Patient intervention (20 weekly group sessions followed by 12 monthly telephone counseling contacts focusing on weight loss, DASH dietary pattern, exercise, and reduced sodium intake)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Combination of physician and patient interventions
Number of subjects: 574
Study: 17998178

Group type: EXPERIMENTAL
Intervention: Highly cross-linked Durasul polyethylene inserts
Number of subjects: 102

Group type: COMPARATOR
Intervention: Contemporary Sulene polyethylene inserts
Number of subjects: 102
Study: 14757463

Group type: EXPERIMENTAL
Intervention: Infrainguinal bypass grafts
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Above knee anastomoses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Below knee grafts
Number of subjects: 30
Study: 11302475

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EACA
Number of subjects: 0
Study: 9803706

Group type: EXPERIMENTAL
Intervention: Single-session, skill-based sexual risk reduction intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: AIDS-education-only condition
Number of subjects: 0
Study: 7536028

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin and teniposide (CBDCA/VM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine (PAV-CyMOC)
Number of subjects: 61
Study: 2496616

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 71397

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31605835

Group type: EXPERIMENTAL
Intervention: Emotional Working Memory Training (eWMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Training (CT)
Number of subjects: 40
Study: 31370223

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri V3401 (5 × 10^9 colony-forming units)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 28663651

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg/4 ml
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline 4 ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 25970229

Group type: EXPERIMENTAL
Intervention: Propofol at 0.6 mg/kg with additional doses of 10-20 mg until OAA/S score 2-4
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dexmedetomidine at a loading dose of 1 μg/kg over 10 minutes followed by 0.5 μg/kg/h infusion until OAA/S score 2-4
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 34
Study: 22915314

Group type: EXPERIMENTAL
Intervention: EEA-relevant context specified (surviving on the savannah/grasslands)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No context specified (simply trying to stay alive)
Number of subjects: 0